A multicentre,open-label,prospective,observational study to evaluate effectiveness and safety of repeated intravitreal injections of Lucentis® in patients with wet age-related macular degeneration over a 12-month observational period in a real-world setting
Phase 4
Completed
- Conditions
- Health Condition 1: null- Patients diagnosed with wet Age related Macular Degeneration
- Registration Number
- CTRI/2013/08/003933
- Lead Sponsor
- ovartis India Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 3000
Inclusion Criteria
�Presence of exudative age-related macular degeneration.
�Patients for whome a therapy with Lucentis� is medically indicated.
�Patients who consent to have their data collected. Patients will not need to consent to taking the drug, as their treatment is decided before entry into the study and is part of their medical care.
Exclusion Criteria
Any contra-indication according to local Summary of Product Characteristics or Prescribing Information (SmPC or PI) of Lucentis®.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method